$CORT

Pomerantz Law Firm files class action lawsuit against $CORT after FDA rejection of relacorilant causes 50.4% stock decline. Investors urged to act by April 21, 2026 deadline.

Lawsuit filed against $CORT alleging executives made false statements about relacorilant's clinical strength and FDA approval prospects, concealing regulatory concerns.

Corcept Therapeutics faces class action lawsuit alleging investor deception over failed relacorilant drug trial. Stock plunged 50.4% after FDA rejection.

Hagens Berman alerts $CORT investors to April 21 lead plaintiff deadline in securities fraud lawsuit over failed relacorilant drug approval and alleged FDA warning concealment.

Rosen Law Firm urges Corcept Therapeutics investors with losses exceeding $100K to join securities class action before April 21, 2026 deadline over alleged FDA application misrepresentations.

Class action lawsuit filed against Corcept Therapeutics alleging executives made false statements about relacorilant's clinical strength and FDA approval prospects.

Corcept Therapeutics ($CORT) faces securities lawsuit over alleged false FDA statements on relacorilant. Lead plaintiff deadline: April 21, 2026.

Hagens Berman alerts $CORT investors to April 21 lead plaintiff deadline in securities fraud class action alleging concealment of FDA concerns about relacorilant ahead of rejection.

Corcept Therapeutics faces class action lawsuit for allegedly misleading investors about relacorilant's FDA prospects. Stock plummeted 50.4% after FDA rejection; investors from October 2024-December 2025 eligible to sue.

Law firm Levi & Korsinsky filed class action suit against $CORT alleging fraud regarding relacorilant FDA approval prospects between October 2024 and December 2025.

Hagens Berman launches securities class action against $CORT after FDA rejects lead drug relacorilant, citing insufficient evidence. Stock plummeted 50% on December 31, 2025.

Class action filed against $CORP alleging securities fraud over misleading statements about relacorilant clinical trials and FDA regulatory prospects.

Three companies face shareholder class actions alleging material misstatements on clinical trials, operations, and expenses. Lead plaintiff deadlines set for April 2026.

Class action lawsuit filed against Corcept Therapeutics alleging securities fraud over misleading statements about relacorilant clinical trials and FDA approval prospects.

Rosen Law Firm solicits Corcept investors in securities class action over alleged misstatements regarding relacorilant clinical trials and FDA approval prospects.

Class action lawsuit filed against Corcept Therapeutics alleging false statements about relacorilant drug's clinical strength and FDA approval prospects.

$CORT faces securities fraud lawsuit alleging false statements about relacorilant's FDA approval status. Investors from October 2024-December 2025 can join class action with Schall Law Firm.

Corcept Therapeutics faces class action lawsuit alleging misrepresentation of relacorilant clinical trial data and FDA approval prospects. Investors from Oct 2024-Dec 2025 may seek compensation.

Corcept Therapeutics faces securities class action after FDA rejected relacorilant, causing 50% stock collapse. Investors have until April 21 to file claims.

Hagens Berman files class action against $CORT over alleged concealment of FDA warnings. Stock plunged 50% after December rejection, erasing $2.5B in market value.